Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial Meeting Abstract
| Authors: | Hollebecque, A.; Borad, M.; Goyal, L.; Schram, A.; Park, J. O.; Cassier, P. A.; Kamath, S. D.; Meng, D. T. W.; Dotan, E.; Kim, R.; Sahai, V.; Oh, D. Y.; Liao, C. Y.; Millward, M.; Perez, D. R.; Ferte, C.; Blakesley, R.; Wolf, B.; Subbiah, V.; Kelley, R. K. |
| Abstract Title: | Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S1381 |
| Language: | English |
| ACCESSION: | WOS:000866211602416 |
| DOI: | 10.1016/j.annonc.2022.08.006 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA12 -- Source: Wos |
